Status:
UNKNOWN
Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis
Lead Sponsor:
Mazandaran University of Medical Sciences
Conditions:
Multiple Sclerosis
Hypogammaglobulinemia
Eligibility:
All Genders
18+ years
Brief Summary
B cells are considered major contributors to multiple sclerosis (MS) pathogenesis, a role that has taken on renewed importance with the advent of B-cell-depleting therapies. Rituximab is being increas...
Detailed Description
This is a prospective study which will be conducted in an educational medical hospitals in Sari, Iran.Adult patients with diagnosis of multiple sclerosis compatible with 2017 McDonald criteria and his...
Eligibility Criteria
Inclusion
- diagnosis of multiple sclerosis compatible with 2017 McDonald criteria
- history of treatment with ritximab at least for 18 month
- written informed consent
Exclusion
- history of IVIG intake in 3 past month
- history of plasmapheresis in 3 past month
- unknown vaccination history
- any indication for concurrent use of immunomodulator or immunosuppressor drug
Key Trial Info
Start Date :
February 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT04283747
Start Date
February 28 2020
End Date
December 1 2022
Last Update
July 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bu Ali Sina hospital
Sari, Iran